Exelixis Inc (NASDAQ: EXEL) on Friday, soared 1.03% from the previous trading day, before settling in for the closing price of $42.60. Within the past 52 weeks, EXEL’s price has moved between $20.40 and $48.85.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 17.51% annually for the last half of the decade. The company achieved an average annual earnings per share of 50.10%. With a float of $263.95 million, this company’s outstanding shares have now reached $275.03 million.
In an organization with 1147 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 96.78%, operating margin of 33.15%, and the pretax margin is 36.45%.
Exelixis Inc (EXEL) Insider Updates
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Exelixis Inc is 3.21%, while institutional ownership is 93.13%. The most recent insider transaction that took place on May 20 ’25, was worth 1,515,091. In this transaction EVP, Commercial of this company sold 34,387 shares at a rate of $44.06, taking the stock ownership to the 412,072 shares. Before that another transaction happened on May 21 ’25, when Company’s Director sold 4,544 for $44.29, making the entire transaction worth $201,254. This insider now owns 32,470 shares in total.
Exelixis Inc (EXEL) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 50.10% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 31.27% during the next five years compared to 11.55% growth over the previous five years of trading.
Exelixis Inc (NASDAQ: EXEL) Trading Performance Indicators
Exelixis Inc (EXEL) is currently performing well based on its current performance indicators. A quick ratio of 3.44 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.11. Likewise, its price to free cash flow for the trailing twelve months is 14.30.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.20, a number that is poised to hit 0.64 in the next quarter and is forecasted to reach 3.04 in one year’s time.
Technical Analysis of Exelixis Inc (EXEL)
Let’s dig in a bit further. During the last 5-days, its volume was 3.06 million. That was better than the volume of 2.88 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 11.85%. Additionally, its Average True Range was 1.52.
During the past 100 days, Exelixis Inc’s (EXEL) raw stochastic average was set at 65.72%, which indicates a significant increase from 53.96% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 81.72% in the past 14 days, which was higher than the 47.86% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $38.48, while its 200-day Moving Average is $33.66. However, in the short run, Exelixis Inc’s stock first resistance to watch stands at $43.37. Second resistance stands at $43.71. The third major resistance level sits at $44.28. If the price goes on to break the first support level at $42.46, it is likely to go to the next support level at $41.89. Assuming the price breaks the second support level, the third support level stands at $41.55.
Exelixis Inc (NASDAQ: EXEL) Key Stats
Market capitalization of the company is 11.74 billion based on 272,708K outstanding shares. Right now, sales total 2,169 M and income totals 521,270 K. The company made 555,450 K in profit during its latest quarter, and 159,620 K in sales during its previous quarter.
